Manufacturing functional induced pluripotent stem cell (iPSC)-derived cells with consistent quality is a crucial, yet challenging step to effectively integrate iPSC technology in drug discovery or tissue engineering. iPSCs are ideal for those purposes as they can be patient-specific, have unlimited self-renewal and can potentially differentiate into any cell type in the body. However, iPSC differentiation is a complex biological process influenced by multiple cell-line and process related variables, hindering standardization and consistency. Consequently, iPSC manufacturing often entails substantial expenses and time-consuming efforts.
With over a decade leading iPSC innovation, Ncardia has successfully established standard and scalable procedures for multiple cell lineages, utilizing both proprietary and external iPSC lines. The substantial expertise gained with cardiac (mesodermal) and neuronal (ectodermal) lineages is now expanded to encompass endodermal derivatives, widely considered as one of the most intricate lineages within the iPSC field.
In this webinar, our senior scientist Mariana Argenziano, PhD will present how Ncardia developed differentiation procedures for the four main cell types found in the lung. She will discuss process optimization and critical quality control steps to deliver high quality and reproducible batches of functional iPSC-derived cells. These protocols enable the production of large quantities of lung cells which can be used for a range of applications, including disease modeling, drug discovery, and tissue engineering.